Spatial and temporal patterns of cortical mean diffusivity in Alzheimer's disease and suspected non-Alzheimer's disease pathophysiology

Alzheimers Dement. 2024 Oct;20(10):7048-7061. doi: 10.1002/alz.14176. Epub 2024 Aug 12.

Abstract

Introduction: The spatial and temporal patterns of cortical mean diffusivity (cMD), as well as its association with Alzheimer's disease (AD) and suspected non-Alzheimer's pathophysiology (SNAP), are not yet fully understood.

Methods: We compared baseline (n = 617) and longitudinal changes (n = 421) of cMD, cortical thickness, and gray matter volume and their relations to vascular risk factors, amyloid beta (Aβ), and tau positron emission tomography (PET), and longitudinal cognitive decline in Aβ PET negative and positive older adults.

Results: cMD increases were more sensitive to detecting brain structural alterations than cortical thinning and gray matter atrophy. Tau-related cMD increases partially mediated Aβ-related cognitive decline in AD, whereas vascular disease-related increased cMD levels substantially mediated age-related cognitive decline in SNAP.

Discussion: These findings revealed the dynamic changes of microstructural and macrostructural indicators and their associations with AD and SNAP, providing novel insights into understanding upstream and downstream events of cMD in neurodegenerative disease.

Highlights: Cortical mean diffusivity (cMD) was more sensitive to detecting structural changes than macrostructural factors. Tau-related cMD increases partially mediated amyloid beta-related cognitive decline in Alzheimer's disease (AD). White matter hyperintensity-related higher cMD mainly explained the age-related cognitive decline in suspected non-Alzheimer's pathophysiology (SNAP). cMD may assist in tracking earlier neurodegenerative signs in AD and SNAP.

Keywords: Alzheimer's disease; age; cortical mean diffusivity; suspected non‐Alzheimer's pathophysiology; vascular disease.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease* / diagnostic imaging
  • Alzheimer Disease* / pathology
  • Alzheimer Disease* / physiopathology
  • Amyloid beta-Peptides* / metabolism
  • Cerebral Cortex / diagnostic imaging
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology
  • Cognitive Dysfunction / diagnostic imaging
  • Cognitive Dysfunction / physiopathology
  • Female
  • Gray Matter / diagnostic imaging
  • Gray Matter / pathology
  • Humans
  • Longitudinal Studies
  • Male
  • Positron-Emission Tomography*
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • tau Proteins